{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:49:37Z","timestamp":1791326977069,"version":"4.3.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Advanced esophageal squamous cell carcinoma (ESCC) has a poor prognosis. Chemotherapy combined with immune checkpoint inhibitors is a feasible treatment, but effective treatment modalities need to be explored for its immune resistance. H101, a genetically modified oncolytic adenovirus, represents a promising anti-tumor therapeutic strategy due to its ability to selectively replicate in and lyse cancer cells while sparing normal tissues. H101 has shown clinical efficacy in treating nasopharyngeal carcinoma and hepatocellular carcinoma. However, its therapeutic potential in ESCC remains understudied, with limited reports available. We reported a case of a patient with multiple relapses of advanced ESCC who exhibited a progression-free survival (PFS) of 15.5 months following the administration of first-line chemotherapy in conjunction with immunotherapy. At first recurrence, the patient received H101 injection in metastatic lymph nodes with chemo- and immunotherapy, demonstrating a reduction in the left cervical lymph node from 29.1\u00d712.9 mm to 24.6\u00d710.36 mm at 25 days post-injection, and ultimately achieving a PFS of 30 months. During the second recurrence, after undergoing three cycles of the aforementioned combined treatment regimen, the patient experienced significant alleviation of their disease. Following the H101 injection, we noted that the patient experienced transient fever, lymph nodes at both injection and non-injection sites subsided, pathological complete response was achieved, and PFS was significantly prolonged. We also observed significant increases in the expression of CD3, CD4, CD8, CD20 and IL-1\u03b2 after two relapsed H101 treatments based on multiplex immunofluorescence analysis. Intralymphatic injection of H101 combined with chemotherapy and immunotherapy may represent a promising clinical strategy for advanced ESCC patients with recurrent lymph node metastasis.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1610058","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T04:10:47Z","timestamp":1751256647000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Overcoming immune resistance in advanced esophageal squamous cell carcinoma with recombinant human adenovirus type 5 by impacting the immune microenvironment: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhongting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4410","article-title":"Immunotherapy for advanced esophageal squamous cell carcinoma-renewed enthusiasm and a lingering challenge","volume":"7","author":"DaSilva","year":"2021","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115610","article-title":"Tumor associated macrophages in esophageal squamous carcinoma: promising therapeutic implications","volume":"167","author":"Zhang","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101896","article-title":"Mitochondria-related chemoradiotherapy resistance genes-based machine learning model associated with immune cell infiltration on the prognosis of esophageal cancer and its value in pan-cancer","volume":"42","author":"Liu","year":"2024","journal-title":"Transl Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0275","article-title":"Progress in oncolytic viruses modified with nanomaterials for intravenous application","volume":"20","author":"Chen","year":"2023","journal-title":"Cancer Biol Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102239","article-title":"The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study","volume":"9","author":"Yi","year":"2024","journal-title":"ESMO Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15101","article-title":"Effectiveness and safety of human type 5 recombinant adenovirus (H101) in Malignant tumor with Malignant pleural effusion and ascites: A multicenter, observational, real-world study","volume":"14","author":"Wang","year":"2023","journal-title":"Thorac Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.752504","article-title":"A recombinant human adenovirus type 5 (H101) combined with chemotherapy for advanced gastric carcinoma: A retrospective cohort study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003914","article-title":"Intratumoral injection of oncolytic virus (H101) in combination with concurrent chemoradiotherapy for locally advanced cervical cancer","volume":"33","author":"Zhang","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13947","article-title":"Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non-small cell lung cancer: A case report","volume":"12","author":"Zhang","year":"2021","journal-title":"Thorac Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-03931-4","article-title":"Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: A case report","volume":"148","author":"Zhao","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","article-title":"Phase I dose-escalation study of endoscopic intratumoral injection of obp-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments","volume":"153","author":"Shirakawa","year":"2021","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41698-020-00135-2","article-title":"Different pathologic responses to neoadjuvant anti-pd-1 in primary squamous lung cancer and regional lymph nodes","volume":"4","author":"Ling","year":"2020","journal-title":"NPJ Precis Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.820566","article-title":"Case report: durable complete response after combined immunotherapy following resection of primary tumor in a gallbladder cancer patient with distant metastatic lymph nodes of favorable immune-microenvironment","volume":"13","author":"Yi","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115627","article-title":"Advancements and challenges in oncolytic virus therapy for gastrointestinal tumors","volume":"168","author":"Li","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1038\/s41467-024-49286-x","article-title":"Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response","volume":"15","author":"Webb","year":"2024","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.17","article-title":"T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses","volume":"23","author":"Taipale","year":"2015","journal-title":"Mol Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e32197","DOI":"10.1371\/journal.pone.0032197","article-title":"Activation of a helper and not regulatory human cd4+ T cell response by oncolytic H-1 parvovirus","volume":"7","author":"Moral\u00e8s","year":"2012","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004762","article-title":"Oncolytic virus expressing pd-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with ctla-4 or tim-3 blockade","volume":"10","author":"Ju","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2023.102.38","article-title":"Predictive value of peripheral blood biomarkers in the treatment of Lung cancer patients with anti pd-1 immunotherapy","volume":"26","author":"Su","year":"2024","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1041126","article-title":"The predictive value of peripheral blood cells and lymphocyte subsets in oesophageal squamous cell cancer patients with neoadjuvant chemoradiotherapy","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e28729","DOI":"10.1002\/jmv.28729","article-title":"Application of oncolytic virus in tumor therapy","volume":"95","author":"Huang","year":"2023","journal-title":"J Med Virol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing pd-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.32604\/or.2024.055746","article-title":"Oncolytic adenovirus H101 enhances the anti-tumor effects of pd-1 blockade via cd47 downregulation in tumor cells","volume":"33","author":"Qiao","year":"2025","journal-title":"Oncol Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of ifn-\u0393 in tumor progression and regression: A review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"biomark Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e21549","DOI":"10.1096\/fj.202002566R","article-title":"Role of tcf-1 in differentiation, exhaustion, and memory of cd8(+) T cells: A review","volume":"35","author":"Zhang","year":"2021","journal-title":"FASEB J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.04.004","article-title":"Combination of cetuximab and oncolytic virus canerpaturev synergistically inhibits human colorectal cancer growth","volume":"13","author":"Wu","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009336","article-title":"Phase I study of a recombinant attenuated oncolytic virus, medi5395 (Ndv-gm-csf), administered systemically in combination with durvalumab in patients with advanced solid tumors","volume":"12","author":"Davar","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1610058\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T04:10:49Z","timestamp":1751256649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1610058\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1610058"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1610058","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"1610058"}}